A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

@article{Sasaki2011ANA,
  title={A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.},
  author={Takaaki Sasaki and Jussi Koivunen and Atsuko Ogino and Masahiko Yanagita and Sarah Nikiforow and Wei Zheng and Christopher S. Lathan and J. Paul Marcoux and Jinyan Du and Katsuhiro Okuda and Marzia Capelletti and Takeshi Shimamura and Dalia Ercan and Magda Stumpfova and Yun Xiao and Stanislawa Weremowicz and Mohit Butaney and St{\'e}phanie H{\'e}on and Keith D. Wilner and James G. Christensen and Michel J Eck and Kwok-kin Wong and Neal I Lindeman and Nathanael S Gray and Scott J Rodig and Pasi Antero J{\"a}nne},
  journal={Cancer research},
  year={2011},
  volume={71 18},
  pages={6051-60}
}
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we report two mechanisms of ALK TKI resistance identified from a crizotinib-treated non-small cell lung cancer (NSCLC) patient and in a cell line generated from the resistant tumor (DFCI076) as well as… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS